ArticleInternational journal of molecular sciences2023
Induced Heteroresistance in Carbapenem-Resistant
Open access · goldAbstract read
In one paragraph
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 18 citations in OpenAlex.
- Cefiderocol nonsusceptibility among carbapenem-resistantAntimicrobial agents and chemotherapy · 2026Article
- Biofilm Formation and the Pore ProteinsAntibiotics (Basel, Switzerland) · 2026Article
- Human serum albumin and biological fluids reduce cefiderocol activity in carbapenem-resistant gram-negative bacteria.International journal of antimicrobial agents · 2026Article
- Structural and Kinetic Variability of Pathogen Cyclophilins: Functional Diversification and Therapeutic Potential.ACS infectious diseases · 2026Review
- Vitamin B12 promotes cefiderocol resistance and small-colony variants in carbapenem-resistantmBio · 2026Article
- Nutrient-driven small-colony variants as an adaptive outcome in Carbapenem-resistantCurrent research in microbial sciences · 2026Article
- Therapeutic challenges and emerging strategies against carbapenem-resistantCurrent research in microbial sciences · 2026Review
- Siderophore cephalosporins.EcoSal Plus · 2025Review
- Spontaneous Emergence of Cefiderocol Resistance inAntibiotics (Basel, Switzerland) · 2025Article
- From Clinical Trials to Real-World Experiences: Evidence About Cefiderocol Use and Potential Role in Empirical Therapy.Infectious diseases and therapy · 2025Review
- The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-ResistantMicroorganisms · 2025Review
- Iron-dependent mechanisms inJAC-antimicrobial resistance · 2025Review
- Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance.Journal of fungi (Basel, Switzerland) · 2025Review
- Carbapenem-resistant Gram-negative bacteria exhibiting clinically undetected cefiderocol heteroresistance leads to treatment failure in a murine model of infection.Frontiers in microbiology · 2025Article
- Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.Current issues in molecular biology · 2024Review
- Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistantMicrobiology spectrum · 2024Article
- Carbapenem-resistant Acinetobacter baumannii (CRAB): metabolic adaptation and transcriptional response to human urine (HU).Scientific reports · 2024Article
- Unveiling the Secrets ofInternational journal of molecular sciences · 2024Review
- Carbapenem-resistant Acinetobacter baumannii (CRAB): metabolic adaptation and transcriptional response to human urine (HU).Research square · 2024Article
- Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-ResistantAntibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 3 countries.
Vyanka MezcordCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.ORCID 0000-0003-1896-8450
Jenny EscalanteCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.
Brent NishimuraCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.
German M TragliaUnidad de Genómica y Bioinformática, Departamento de Ciencias Biológicas, CENUR Litoral Norte, Universidad de la República, Salto 50000, Uruguay.ORCID 0000-0002-4780-5311
Rajnikant SharmaUNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
Quentin ValléUNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
Marisel R TuttobeneÁrea Biología Molecular, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario 2000, Argentina.
Tomás SubilsInstituto de Procesos Biotecnológicos y Químicos de Rosario (IPROBYQ, CONICET-UNR), Rosario 2000, Argentina.
Ingrid MarinCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.
Fernando PasteranNational Regional Reference Laboratory for Antimicrobial Resistance (NRL), Servicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, ANLIS Dr. Carlos G. Malbrán, Buenos Aires 1282, Argentina.ORCID 0000-0001-5840-5869
Luis A ActisDepartment of Microbiology, Miami University, Oxford, OH 45056, USA.ORCID 0000-0001-9644-9088
Marcelo E TolmaskyCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.ORCID 0000-0002-6298-7811
Robert A BonomoResearch Service and GRECC, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH 44106, USA.
Gauri RaoUNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
María S RamirezCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.ORCID 0000-0002-9904-7890
California State University, Fullerton · USUniversity of North Carolina at Chapel Hill · USConsejo Nacional de Investigaciones Científicas y Técnicas · ARAdministración Nacional de Laboratorios e Institutos de Salud · ARGeriatric Research Education and Clinical Center · USMiami University · USUniversidad de la República de Uruguay · UY
Funding
Minority Health and Health Disparities International Research Training ProgramT37MD001368 · NIMHD · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2005 to 2024
$3.9MDEALING WITH ANTIBIOTIC RESISTANCE--ANTISENSE TECHNOLOGYR15AI047115 · NIAID · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2000 to 2022
$1.8MIdentifying host human products responsible for natural transformation of resistance traits in Acinetobacter sppSC3GM125556 · NIGMS · CALIFORNIA STATE UNIVERSITY FULLERTON · PI RAMIREZ, MARIA SOLEDAD · 2018 to 2025
$851kNIAID NIH HHS R15 AI047115NIGMS NIH HHS SC3 GM125556NIH HHS SC3GM125556 to M.S.R., R01AI100560, R01AI063517, R01AI072219 to R.A.B., and 2R15 AI047115 to M.E.TNIMHD NIH HHS MHRT 2T37MD001368
Abstract
Infections caused by Carbapenem-resistant
Indexed as
Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsCefiderocolHumansIronMicrobial Sensitivity TestsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsCefiderocolIronAcinetobacter baumanniiantibiotic susceptibility assayscarbapenem-resistancecefiderocolhuman pleural fluidNDM-1static killing-assaywhole-genome sequencing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.